About Icons

Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

Drug Description in Trials / DrugBank / KEGG DRUG

Search results

No.

Drug (Description in trials)

DrugBank

KEGG DRUG

KEGG GENES

KEGG PATHWAY

Disease ID

1

ANTI-VON willebrand factor nanobody, caplacizumab

-

-

-

-

[1] 64 💬

2

ANTI-VON willebrand factor nanobody, INN = caplacizumab

[1] Caplacizumab (Caplacizumab)

[1] Caplacizumab (Caplacizumab, Caplacizumab, Caplacizumab-yhdp) 💬

[1] VWF 💬

[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬

[1] 64 💬

3

[1] Caplacizumab (Caplacizumab)

[1] Caplacizumab (Caplacizumab, Caplacizumab, Caplacizumab-yhdp) 💬

[1] VWF 💬

[8] Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬

[2] 63, 64 💬